Brings the Gyros nanoliter-scale immunoassay platform to biopharmaceutical and vaccine manufacturers in key growth markets
Gyros AB, a leader in utilization of microfluidic technologies to miniaturize and automate immunoassays, announced today that GE Healthcare Life Sciences has become sole distributor for the company’s nanoliter-scale immunoassay platform in China, Taiwan and Hong Kong. The Gyros platform (www.gyros.com) is used by major biopharmaceutical companies and their service providers to improve productivity and efficiency during the development of biotherapeutics and vaccines, boosting time-critical workflows and helping to meet regulatory demands.
Commenting on the announcement, Erik Walldén, CEO at Gyros, said, “The acceptance of our nanoliter-scale immunoassay platform continues to grow within the global biopharmaceutical industry. Expansion into the Asian markets through an experienced and respected network of distributors will ensure the highest possible standards of service and support for customers interested in our products, which we see as one of the key factors for commercial success in this region. Having recently signed with GE Healthcare Japan, we are very pleased to extend our collaboration into China, Taiwan and Hong Kong through such a well-established supplier.”
Duncan Yu, General Manager, Life Sciences of GE Healthcare Greater China , added, “We are delighted to have signed this agreement with Gyros which will help us further expand our offering of value-added and innovative technologies to the rapidly growing biopharmaceutical industry in China, Taiwan and Hong Kong. The Gyros immunoassay platform offers manufacturers of biopharmaceuticals and vaccines the potential to make substantial improvements in productivity and is an excellent complement to our own extensive range of analytical technologies for the biopharmaceutical industry including Biacore™ and MicroCal™ systems.”